enGene Holdings Shareholders Approve Board and Auditor Slate
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
enGene Holdings ( (ENGN) ) has provided an update.
At its Annual General Meeting held on June 9, 2026, enGene Therapeutics Inc. reported that shareholders representing approximately 83.89% of its 66,989,466 outstanding common shares were present or represented by proxy, underscoring strong investor engagement. All director nominees, including Philip Astley-Sparke, Ronald H.W. Cooper, Dr. William Grossman and Michael Heffernan, were elected with substantial support, and shareholders overwhelmingly approved the appointment and remuneration of the company’s auditor, reinforcing continuity in governance and financial oversight.
The voting outcomes signal broad shareholder confidence in enGene’s leadership and strategic direction, which may strengthen the company’s position as it pursues its gene-therapy programs. High turnout and near-unanimous approval of both the board slate and auditor arrangement suggest stable corporate governance, a factor that could support investor sentiment and facilitate execution of long-term operational plans.
The most recent analyst rating on (ENGN) stock is a Hold
with a $2.00 price target.
To see the full list of analyst forecasts on enGene Holdings stock,
see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
Overall score reflects weak financial performance (no revenue, heavy cash burn) and bearish technicals (price well below moving averages with negative momentum). A relatively strong balance sheet and a positive corporate update tied to a commercialization push provide partial support, but valuation is not compelling due to losses and no dividend.
To see Spark’s full report on ENGN stock,
click here.
More about enGene Holdings
enGene Therapeutics Inc. operates in the biopharmaceutical industry, focusing on the development of genetic medicines. The company’s work centers on therapeutics that leverage gene-based technologies, targeting unmet medical needs in its chosen markets.
Average Trading Volume: 1,559,365
Technical Sentiment Signal: Sell
Current Market Cap: $111.9M
See more insights into ENGN stock on TipRanks’ Stock Analysis page.
